Perrigo granted review over €1.64bn Revenue tax bill

This report is a localnews.ie summary based on public court reporting and records; sources are listed below.

Perrigo was granted leave for a judicial review of a €1.64 billion Revenue tax assessment in the High Court on 25 February 2019.

The assessment concerns tax on Elan’s 2013 sale of intellectual property linked to the multiple sclerosis drug Tysabri. Perrigo says the proceeds were trading income taxed at 12.5 per cent, while Revenue argues the sale should have been taxed as a capital gain at 33 per cent. The company’s tax appeal was put on hold pending the judicial review, which was returned to April.